You are here

New Robotic Aid for Drugfree Depression Treatment

Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants

MagVenture has added the new FDA-approved robotic platform to its clinical system. The TMS-Cobot, will help further elevate the rapidly growing field of neuromodulation, commonly known as Transcranial Magnetic Stimulation (TMS).

Transcranial Magnetic Stimulation (TMS) therapy–– is an effective, non-invasive option for the large number of patients who fail to respond to antidepressants. During treatment, magnetic pulses are applied with a magnetic coil to a certain part of the patient’s brain. This area is the entry-point for treatment as the pulses reach the neural network that controls mood and emotion, potentially alleviating the depression. Patients are fully awake during treatment and can return to their normal activities immediately following the TMS session. Typically, patients will receive a total of 20–30 sessions, one per weekday.

The new robotic TMS-Cobot provides continuous tracking of the patient’s possible head movements during treatment. It also reduces the manual coil-handling time for TMS operators, which is a key factor for clinics that treat many patients.

TMS-Cobot is FDA-indicated for the spatial positioning and orientation of MagVenture’s TMS Therapy system treatment coil.

Source: MagVenture, February 20, 2019

Recent Headlines

Drug resistance in HIV patients has nearly tripled since 2001
New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI